Jump Financial LLC Invests $1.21 Million in Enovis Corporation $ENOV

Key Points

• Jump Financial LLC acquired 31,703 shares of Enovis Corporation, valued at approximately $1,211,000, indicating institutional interest in the company.
• Several analysts lowered their target prices for Enovis, with the consensus target now at $51.00, while maintaining a "Buy" rating.
• Enovis reported earnings per share of $0.79 for the last quarter, surpassing estimates, with revenues increasing by 7.5% year-over-year.

Jump Financial LLC acquired a new position in Enovis Corporation (NYSE:ENOV - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 31,703 shares of the company's stock, valued at approximately $1,211,000. Jump Financial LLC owned approximately 0.06% of Enovis at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. grew its holdings in Enovis by 0.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 6,207,768 shares of the company's stock worth $237,199,000 after buying an additional 44,632 shares in the last quarter. Humankind Investments LLC grew its holdings in Enovis by 8.6% in the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company's stock worth $217,000 after buying an additional 452 shares in the last quarter. Quantbot Technologies LP bought a new position in Enovis in the 1st quarter worth approximately $1,973,000. Dimensional Fund Advisors LP grew its holdings in Enovis by 1.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,927,340 shares of the company's stock worth $111,852,000 after buying an additional 27,894 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in Enovis in the 1st quarter worth approximately $1,069,000. 98.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ENOV shares. Canaccord Genuity Group decreased their price objective on Enovis from $70.00 to $58.00 and set a "buy" rating for the company in a report on Friday, August 8th. Needham & Company LLC cut their target price on Enovis from $57.00 to $49.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. UBS Group cut their target price on Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Wells Fargo & Company cut their target price on Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. Finally, JMP Securities cut their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $51.00.

Enovis Price Performance

Shares of NYSE:ENOV traded up $0.29 on Monday, reaching $30.88. 934,252 shares of the company traded hands, compared to its average volume of 1,131,516. Enovis Corporation has a fifty-two week low of $25.47 and a fifty-two week high of $49.83. The company's 50 day moving average is $30.06 and its 200-day moving average is $33.48. The stock has a market capitalization of $1.77 billion, a PE ratio of -2.17 and a beta of 1.68. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.79 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.05. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company had revenue of $564.50 million during the quarter, compared to the consensus estimate of $555.80 million. During the same quarter in the prior year, the firm earned $0.62 EPS. The company's quarterly revenue was up 7.5% compared to the same quarter last year. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. As a group, analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enovis news, SVP Bradley J. Tandy bought 3,200 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was acquired at an average price of $31.41 per share, with a total value of $100,512.00. Following the completion of the transaction, the senior vice president directly owned 43,515 shares in the company, valued at approximately $1,366,806.15. This represents a 7.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Phillip Benjamin (Ben) Berry bought 2,500 shares of the firm's stock in a transaction dated Wednesday, August 20th. The stock was acquired at an average cost of $29.71 per share, with a total value of $74,275.00. Following the transaction, the chief financial officer owned 116,729 shares of the company's stock, valued at $3,468,018.59. This trade represents a 2.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. 2.70% of the stock is owned by corporate insiders.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.